Swedish Doubts About Avodart Sink Prostate Cancer Prevention Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline halts global pursuit of a prostate cancer risk reduction claim for its 5-alpha reductase inhibitor dutasteride after Swedish regulators echo FDA concerns about clinical benefit and safety.